PARP inhibitors: current status and implications for anticancer therapeutics
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-9378
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PARP inhibitors: current status and implications for anticancer therapeutics ; volume:8 ; number:1 ; day:2 ; month:12 ; year:2013 ; pages:1-3 ; date:12.2013
Infectious agents and cancer ; 8, Heft 1 (2.12.2013), 1-3, 12.2013
- Urheber
-
Usmani, Hadi
- Beteiligte Personen und Organisationen
-
Hussain, Syed Ather
Sheikh, Asfandyar
SpringerLink (Online service)
- DOI
-
10.1186/1750-9378-8-46
- URN
-
urn:nbn:de:1111-2016072626262
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Usmani, Hadi
- Hussain, Syed Ather
- Sheikh, Asfandyar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitors
Akt inhibitors: mechanism of action and implications for anticancer therapeutics
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Targeting CDK9 for anti-cancer therapeutics
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Advances and perspectives of PARP inhibitors
PARP inhibitors in the management of breast cancer: current data and future prospects
Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics
PARP Inhibitors in Ovarian Cancer: A Review
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitors
Akt inhibitors: mechanism of action and implications for anticancer therapeutics
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Targeting CDK9 for anti-cancer therapeutics
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Advances and perspectives of PARP inhibitors
PARP inhibitors in the management of breast cancer: current data and future prospects
Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics
PARP Inhibitors in Ovarian Cancer: A Review
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitors
Akt inhibitors: mechanism of action and implications for anticancer therapeutics
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Targeting CDK9 for anti-cancer therapeutics
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Advances and perspectives of PARP inhibitors
PARP inhibitors in the management of breast cancer: current data and future prospects
Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics